PE20142284A1 - Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo - Google Patents

Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo

Info

Publication number
PE20142284A1
PE20142284A1 PE2014001923A PE2014001923A PE20142284A1 PE 20142284 A1 PE20142284 A1 PE 20142284A1 PE 2014001923 A PE2014001923 A PE 2014001923A PE 2014001923 A PE2014001923 A PE 2014001923A PE 20142284 A1 PE20142284 A1 PE 20142284A1
Authority
PE
Peru
Prior art keywords
pharmaceutical dosage
candesartan
manufacture
dosage form
cylexethyl
Prior art date
Application number
PE2014001923A
Other languages
English (en)
Inventor
Adrian Funke
Gunter Meyer
Martina Smikalla
Andreas Meeners
Markus Wirges
Daniela Brock
Sarah Just
Peter Kleinebudde
Klaus Knop
Jochen Axel Zeitler
Rolf-Anton Boeggering
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20142284A1 publication Critical patent/PE20142284A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

SE REFIERE A PROCEDIMIENTOS DE FABRICACION DE UNA FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE A) NIFEDIPINA EN EL NUCLEO LA CUAL SE LIBERA EN EL ORGANISMO DE UNA MANERA CONTROLADA; B) CANDESARTAN CILEXETILO EN LA CAPA DE RECUBRIMIENTO CUYO CONTENIDO MEDIO ES DE 95 A 105%, Y ES DE LIBERACION INMEDIATA; Y OPCIONALMENTE C) UN DIURETICO DE LIBERACION INMEDIATA. TAMBIEN SE REFIERE A LAS FORMAS DE DOSIFICACION FARMACEUTICA QUE SE PUEDEN OBTENER MEDIANTE DICHOS PROCEDIMIENTOS
PE2014001923A 2012-05-07 2013-05-02 Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo PE20142284A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167035 2012-05-07
EP13151946 2013-01-18

Publications (1)

Publication Number Publication Date
PE20142284A1 true PE20142284A1 (es) 2014-12-17

Family

ID=48289160

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001923A PE20142284A1 (es) 2012-05-07 2013-05-02 Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo

Country Status (27)

Country Link
US (1) US9539176B2 (es)
EP (1) EP2846777B1 (es)
JP (1) JP6231553B2 (es)
KR (1) KR20150007297A (es)
CN (1) CN104507459A (es)
AR (1) AR090940A1 (es)
AU (1) AU2013258273A1 (es)
BR (1) BR112014027618A2 (es)
CA (1) CA2872542A1 (es)
CL (1) CL2014002988A1 (es)
CO (1) CO7190241A2 (es)
CR (1) CR20140511A (es)
DO (1) DOP2014000251A (es)
EA (1) EA201492026A1 (es)
EC (1) ECSP14025965A (es)
ES (1) ES2612532T3 (es)
GT (1) GT201400245A (es)
HK (1) HK1204292A1 (es)
IL (1) IL235040A0 (es)
IN (1) IN2014DN09045A (es)
MX (1) MX2014013320A (es)
PE (1) PE20142284A1 (es)
PH (1) PH12014502469A1 (es)
SG (1) SG11201406363VA (es)
TW (1) TW201410266A (es)
UY (1) UY34786A (es)
WO (1) WO2013167453A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9244004B2 (en) * 2013-08-08 2016-01-26 Stichting Sron—Netherlands Institute For Space Research Method and system for inspection of composite assemblies using terahertz radiation
US10071482B2 (en) 2015-08-19 2018-09-11 Ford Global Technologies, Llc Robotic vehicle painting instrument including a terahertz radiation device
US10365229B2 (en) * 2015-12-31 2019-07-30 Kaiser Optical Systems, Inc. Real-time characterization of pharmaceutical tablet coatings using Raman spectroscopy
DE102016222667A1 (de) * 2016-11-17 2018-05-17 Robert Bosch Gmbh Verfahren zum Betrieb einer Anlage zum Herstellen von pharmazeutischen Produkten
US10323932B1 (en) 2017-12-28 2019-06-18 Ford Motor Company System for inspecting vehicle bodies
JP7263047B2 (ja) * 2019-02-25 2023-04-24 沢井製薬株式会社 フィルムコーティング錠剤
CN110411978B (zh) * 2019-07-26 2020-05-22 中国农业大学 一种物料均匀性检测设备及检测方法
JP7312676B2 (ja) 2019-11-13 2023-07-21 ナブテスコ株式会社 ブレーキ異常判定装置、ブレーキ状態記憶装置、異常判定方法、異常判定プログラム、及びブレーキ制御装置
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4426019A (en) 1981-10-15 1984-01-17 The Coca-Cola Company Membrane seal and knife combination for a post-mix beverage dispensing system
US4576604A (en) 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
EP0386440B1 (de) 1989-02-11 1992-08-05 Bayer Ag Arzneimittel mit kontrollierter Wirkstoffabgabe
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5656650A (en) 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
CA2098176C (en) 1990-12-14 2006-12-12 Joseph Weinstock Angiotensin ii receptor blocking compositions
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5178867A (en) 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
AU4221300A (en) 1999-04-06 2000-10-23 Kamal K. Midha Pharmaceutical dosage form for pulsatile delivery of (d-threo)-methylphenidate and a second cns stimulant
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
EP1413315A4 (en) 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
WO2003035039A1 (en) 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
AU2003227472A1 (en) 2002-03-27 2003-10-08 Bayer Aktiengesellschaft Downsized core tablet containing nifedipine
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20060134206A1 (en) 2003-07-24 2006-06-22 Iyer Eswaran K Oral compositions for treatment of diseases
WO2005070398A2 (en) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
WO2005079751A2 (en) 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
WO2005084648A1 (en) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
ES2429941T3 (es) 2005-05-10 2013-11-18 Teva Pharmaceutical Industries, Ltd. Candesartán cilexetilo micronizado estable y métodos para preparar el mismo
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
EP2040780B1 (en) 2006-07-03 2016-01-06 Novo Nordisk A/S Coupling for injection devices
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2008045006A1 (en) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
EP2099431B1 (en) 2006-11-28 2013-06-05 Laboratorios Liconsa, S.A. Stabilized solid pharmaceutical composition of candesartan cilexetil
JP5351490B2 (ja) 2007-10-25 2013-11-27 バイエル薬品株式会社 ニフェジピン含有有核錠剤およびその製法
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
EP2611442B1 (en) 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants

Also Published As

Publication number Publication date
ECSP14025965A (es) 2015-12-31
WO2013167453A1 (en) 2013-11-14
AR090940A1 (es) 2014-12-17
PH12014502469A1 (en) 2014-12-22
KR20150007297A (ko) 2015-01-20
US9539176B2 (en) 2017-01-10
EP2846777A1 (en) 2015-03-18
CR20140511A (es) 2014-12-02
HK1204292A1 (en) 2015-11-13
BR112014027618A2 (pt) 2017-06-27
MX2014013320A (es) 2015-08-10
SG11201406363VA (en) 2014-11-27
ES2612532T3 (es) 2017-05-17
GT201400245A (es) 2015-08-25
CO7190241A2 (es) 2015-02-19
TW201410266A (zh) 2014-03-16
JP6231553B2 (ja) 2017-11-15
IN2014DN09045A (es) 2015-05-22
AU2013258273A1 (en) 2014-11-13
CN104507459A (zh) 2015-04-08
DOP2014000251A (es) 2014-12-31
CL2014002988A1 (es) 2015-03-13
UY34786A (es) 2013-11-29
EA201492026A1 (ru) 2015-09-30
JP2015515999A (ja) 2015-06-04
IL235040A0 (en) 2014-12-31
US20130309302A1 (en) 2013-11-21
CA2872542A1 (en) 2013-11-14
EP2846777B1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
PE20142284A1 (es) Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo
CL2016002310A1 (es) Nuevos compuestos bicíclicos.
CL2015001702A1 (es) Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
PH12016501122A1 (en) Delayed release compositions of linaclotide
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
PE20151301A1 (es) Formulaciones farmaceuticas resistentes a la manipulacion indebida
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
UY35747A (es) Derivados sustituidos de fenilalanina
CL2014002048A1 (es) Compuestos derivados de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados; composicion farmaceutica; y uso en la prevencion y el tratamiento de trastornos autoinmunes, inflamatorios, enfermedades infecciosas, entre otras.
UY35735A (es) Trifluorometilpirimidinonas disustituidas y su uso
UY35745A (es) Derivados sustituidos de fenilalanina
ECSP15030460A (es) Composición de difenidol de liberación prolongada
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
CL2014001323A1 (es) Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
CL2014003361A1 (es) Profarmaco de ácido fosforamidico del compuesto 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida; composicion farmaceutica y uso en el tratamiento o la prevencion de la arritmia.
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
GT201500124A (es) Forma sòlida de un derivado de dihidro-pirido-oxazina

Legal Events

Date Code Title Description
FD Application declared void or lapsed